Big Gain For PDS Biotechnology Corporation

PDS Biotechnology Corporation (PDSB:NASDAQ) rocketted at $0.59, a gain of 47.2%. On Tue, Sep 15, 2026, PDSB:NASDAQ hit a New 2-Week High of $0.59. The stock appeared on our News Catalysts scanner on Tue, Sep 15, 2026 at 04:51 PM in the 'BIOTECH' category. From Tue, Sep 01, 2026, the stock recorded 66.67% Up Days and 50.00% Green Days

The stock spiked on Tue, Sep 15, 2026 at $0.76 with a volume of 363M+.

About PDS Biotechnology Corporation (PDSB:NASDAQ)

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.